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Mammary analogue secretory carcinoma of the salivary glands: a 
diagnostic dilemma 
 
 
Abstract  
Mammary analogue secretory carcinoma (MASC) is a recently identified salivary gland 
neoplasm that can mimic other salivary gland tumours such as acinic cell carcinoma and 
cystadenocarcinoma.  It is distinguished from these by differences in immunohistochemical 
profile and the identification of an ETV6-NTRK3 translocation (12;15)(p13;q25), which is 
also found in secretory carcinomas of the breast. Previous publications have suggested that 
MASC tumours have similar biological behaviour to acinic cell carcinoma.  We report two 
cases of MASC that affected the upper lip, and showed an infiltrative and locally aggressive 
growth pattern that required several operations to ensure clearance of microscopic tumour 
cells. 
 
Keywords: Mammary analogue secretory carcinoma; MASC; salivary gland malignancy; 
minor salivary gland; lip; ETV6-NTRK3 translocation 
 
Introduction  
Mammary analogue secretory carcinoma (MASC) is a rare tumour of the salivary glands that 
was first described by Skálová et al in 2010.1 It usually presents with microcystic architecture 
and low-grade cytological features, and is histomorphologically and immunohistochemically 
similar to secretory carcinoma of the breast. The histological features can resemble other 
salivary tumours such as cystadenocarcinoma and acinic cell carcinoma. Its most commonly 
described site is the major salivary glands, but there are only a handful of reported cases of it 
affecting the minor salivary glands of the lip.
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We report two cases of MASC of the upper lip, which showed locally aggressive biological 
behaviour and required a more aggressive treatment than that adopted for histological mimics 
such as acinic cell carcinoma.  
 
Case 1 
An otherwise healthy 27-year-old woman presented with a one-year history of a slow-
growing 1.5 cm lump, on her right upper lip. Cytological analysis of ultrasound-guided fine 
needle aspirate suggested a salivary gland neoplasm that raised the possibility of acinic cell 
carcinoma. The lesion was excised and histopathological analysis confirmed the diagnosis of 
MASC after immunohistochemical studies had stained for S100 and mammaglobin. It did not 
stain for DOG1. Fluorescent in situ hybridisation confirmed rearrangement of the ETV6 gene. 
Staging scans showed no evidence of metastases. The margins of the specimen were invaded 
on histopathological analysis despite the impression of macroscopic clearance at operation. 
She subsequently had a wedge excision of the scar with a 1cm margin but then required a 
repeat resection after microscopic identification of residual dispersed islands of tumour that 
had reached the margins. The patient had no signs of local or regional recurrence nine months 
after her operation (Figs. 1-3). 
 
Case 2  
A 51-year-old man who used to smoke and had no other relevant medical history presented 
with a three-year history of an asymptomatic, firm, mobile lump in his upper right labial 
mucosa. Histopathological examination of an excisional biopsy specimen together with 
immunohistochemical profile and fluorescent in situ hybridisation again suggested a 
diagnosis of MASC. Staging scans showed no abnormality.  
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The patient had a further excision of the scar with a 1cm margin under general anaesthetic. 
Final histopathological analysis again showed residual tumour with a close margin at the 
deeper aspect of the specimen. The patient declined any further intervention so a policy of  
close follow-up was adopted. There were no signs of local or regional recurrence at his six-
month review. 
 
Discussion  
Because MASC was not recognised as a distinct entity until 2010 it is not listed in the most 
recent 2005 WHO classification of salivary gland tumours.
3
 We know of about 90 cases of 
MASC that have been published - two thirds of which were in the parotid gland, followed by 
the intraoral minor salivary glands and the submandibular gland.
4
  
 
MASC resembles secretory carcinoma of the breast and expresses the same ETV6-NTRK3 
gene fusion protein, which leads to constitutive activation of two major effector pathways - 
the Ras-MAP kinase mitogenic pathway and the phosphatidyl inositol-3-kinase-AKT 
pathway.
5
 This translocation has not been found in conventional salivary acinic cell 
carcinoma.  There are, however, differences in immunohistochemical profile: MASC reacts to 
mammaglobin and S100 while acinic cell carcinoma shows no appreciable expression of these 
markers.
1
 The morphology of these two tumours can be similar, which can lead to errors of 
interpretation.
1,6,7
 
 
Both of these case studies involved minor salivary glands of the upper lip and we managed 
them the same way we would an acinic cell carcinoma. Previous publications have suggested 
that the management of MASC should be similar, but its histological behavior is more 
aggressive and it is difficult to obtain microscopically clear margins despite the impression of 
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adequate macroscopic clearance.
8
 We advise a more aggressive approach to the treatment of 
MASC tumours that affect the minor salivary glands. 
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Figure legends 
Fig. 1. Residual tumour after excision. (Haematoxylin and eosin, original magnification x 
100). 
Fig. 2. Positivity for mammaglobin. (Haematoxylin and eosin, original magnification x 40.) 
Fig. 3. Positivity for S100. (Haematoxylin and eosin, original magnification x 40). 
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Mammary Analogue Secretory Carcinoma (MASC) of the salivary 
glands: a diagnostic dilemma 
 
 
Abstract  
Mammary analogue secretory carcinoma (MASC) is a salivary gland neoplasm that 
was first formally described in 2010. This newly recognised tumour can mimic other 
salivary gland tumours such as acinic cell carcinoma (ACC) and 
cystadenocarcinoma.  They are distinguished from these entities through differences 
in immunohistochemical profile and the identification of an ETV6-NTRK3 
translocation (12;15)(p13;q25) that is also found in secretory carcinomas of the 
breast. Existing literature predicts that MASC tumours have similar biological 
behavior to ACC.  We report 2 cases of MASC affecting the upper lip, which 
demonstrate an infiltrative and locally aggressive growth pattern requiring multiple 
surgical procedures to ensure microscopic tumour clearance. 
Keywords: Mammary analogue secretory carcinoma; MASC; salivary gland 
malignancy; minor salivary gland; lip; ETV6-NTRK3 translocation 
 
Introduction  
Mammary Analogue Secretory Carcinoma (MASC) is a rare salivary gland tumour 
first described by Skálová et al in 2010. These tumours usually present with 
microcystic architecture and low-grade cytological features and bear close 
histomorphological and immunohistochemical resemblance to secretory carcinoma 
(SC) of the breast.1 Histological features of MASC can resemble ACC and other 
salivary tumours such as cystadenocarcinoma. The most commonly described 
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location for MASC is major salivary glands; however, there are only a handful of 
cases affecting the minor salivary glands of the lip reported in the existing literature.2 
We report two cases of MASC affecting the upper lip, which were noted to show 
locally aggressive biological behaviour and required a more aggressive approach to 
treatment to that locally adopted for histological mimics such as ACC.  
 
Case 1 
An otherwise healthy 27-year-old female presented with a one-year history of a slow 
growing 1.5cm lump, on her right upper lip. An ultrasound guided fine needle 
aspiration was carried out and cytological analysis of the aspirate suggested a 
salivary gland neoplasm that raised the possibility of ACC. The patient subsequently 
had the lesion excised for formal histopathological analysis and a diagnosis of MASC 
was made following immunohistochemical studies demonstrating positivity for S100 
and Mammaglobin. Dog1 was negative. Fluorescent in situ hybridisation (FISH) 
studies confirmed an ETV6 gene rearrangement. Staging scans showed no evidence 
of metastatic disease. The margins of the specimen were involved by tumour on 
histopathological analysis despite the impression of macroscopic surgical clearance 
at the time of surgery. She subsequently had formal wedge excision of the scar with 
a 1cm margin but then required repeat surgery following microscopic identification of 
residual dispersed tumour islands reaching the surgical margins. The patient has 
displayed no signs of local or regional recurrence at her 9-month post-surgery review 
(figures. 1-3). 
 
Case 2  
A 51-year-old male ex-smoker with no other relevant medical history presented with 
a 3-year history of an asymptomatic firm, mobile lump in his upper right labial 
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mucosa. An excisional biopsy was carried out under local anaesthetic. The 
histopathological features, immunohistochemical profile and FISH again suggested a 
diagnosis of MASC. Staging scans were unremarkable.  
The patient had a re-excision of the scar with a 1cm margin under general 
anaesthetic. Final histopathological analysis again demonstrated residual tumour 
with a close margin at the deeper aspect of the excision specimen. The patient 
declined to have any further surgery so a close follow-up policy was adopted. There 
have been no signs of local or regional recurrence at his 6-month post-surgery 
review. 
 
Discussion  
MASC was first recognised as a distinct entity in 2010 and so is not listed in the most 
recent 2005 WHO classification of salivary gland tumours.3 Approximately 90 cases 
of MASC have been published - two thirds of which occurred in the parotid gland, 
followed by the intra oral minor salivary glands and the submandibular gland.4  
MASC resembles secretory carcinoma of the breast and expresses the same ETV6-
NTRK3 gene fusion protein, which leads to constitutive activation of two major 
effector pathways - the Ras-MAP kinase mitogenic pathway and the phosphatidyl 
inositol-3-kinase-AKT pathway.5 This translocation has not been found in 
conventional salivary ACC.  There are, however, differences in immunohistochemical 
profile - MASC demonstrate reactivity to Mammaglobin and S100 whilst ACC does 
not show significant expression of these markers.1 The morphology of these two 
tumours can be similar leading to errors of interpretation.1,6,7 
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Both cases presented here involved the minor salivary glands of the upper lip and 
were managed the same way as we would manage an ACC. Existing literature 
suggest that surgical management of MASC probably should be similar to that of 
ACC; however, histologic behavior at this anatomical site appears more aggressive 
with difficulty in obtaining microscopically clear margins despite the surgical 
impression of adequate macroscopic clearance.8 Consequently, we advise 
consideration of a more aggressive surgical approach in MASC tumours affecting the 
minor salivary glands. 
 
Conflict of Interest 
No 
 
Ethics statement/confirmation of patient permission 
Ethics approval: No. Patient consent obtained 
 
References  
1. Skálová A, Vanecek T, Sima R, et al., “Mammary analogue secretory 
carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a 
hitherto undescribed salivary gland tumor entity,” Am J Surg Pathol 
2010;34:599-608. 
2. Kratochvil FJ 3rd, Stewart JC, Moore SR. “Mammary analog secretory 
carcinoma of salivary glands: A report of 2 cases in the lips.” Oral Surg Oral 
Med Oral Pathol Oral Radiol 2012;114:630–635. 
3. Barnes EL, Eveson JW, Reichard P, et al, eds. “World health organization 
classification of tumours. Pathology and genetics of head and neck tumours.” 
Lyon: IARC Press; 2005  
5 
 
4. Takeda M, Kasai T, Morita K, et al. “Cytopathological features of mammary 
analogue secretory carcinoma—review of literature”. Diagn Cytopathol, 
2015;43:131-137. 
5. Fehr A, Löning T, Stenman G.  ”Mammary analogue secretory carcinoma of 
the salivary glands with ETV6-NTRK3 gene fusion.” Am J Surg Pathol 
2011;35:1600-1602 
6. Chiosea SI, Griffith C, Assaad A, et al. ”The profile of acinic cell carcinoma 
after recognition of mammary analogue secretory carcinoma”. Am J Surg 
Pathol 2012;36:343–350. 
7. Bishop JA, Yonescu R, Batista D, et al. ”Most non-parotid “Acinic Cell 
Carcinomas” represent mammary analogue secretory carcinomas.” Am J Surg 
Pathol 2013;37:1053–1057. 
8. Chiosea SI, Grifﬁth C, Assaad A, et al. “Clinicopathological characterization of 
mammary analogue secretory carcinoma of salivary glands”. Histopathology 
2012;61:387–394 
 
 
Figure Captions 
Figure 1. Residual tumour after excision. H+E stained section. Magnification x 100 
Figure 2. Positivity for mammaglobin. Magnification x 40    
Figure 3. Positivity for S100. Magnification x 40 
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